EluNIR – HBR
Enrollment
Completed
TLF, ARC, MACE
Primary Endponit
316
Patients
18 Sites
UK, Israel

Prospective, Post Marketing
Single-Arm Trial

ChampioNIR – First In Human
Enrollment
Completed
30
Patients
4 Sites
Israel

Prospective, open
label, multi-center
single arm study

EluNIR – JNIR
Enrollment
completed
TLF
Primary Endpoint
12 M
Data Reported
104
Patients
10 Sites
Japan

Single arm study
for
regulatory approval

EluNIR – BIONICS
Enrollment
Completed
5.4% TLF
Primary Endpoint
12 M
Data Reported
1,919
Patients
76 Sites
USA, Canada, Europe, Israel

More comers randomized
clinical trial

EluNIR – NIREUS
Enrollment
Completed
0.04 mm
Late-loss at 6M
6 M
Data Reported
302
Patients
31 Sites
Europe, Israel

More comers randomized
clinical trial